| ·基石药业胃肠道间质瘤(GIST)精准靶向药物泰時维获纳入 “... | 2022-06-16 11:26:56 |
| ·基石药业泰時维(阿伐替尼片)在台湾获批上市,用于胃肠道间质瘤 | 2021-05-06 11:27:00 |
| ·欧批准Ayvakit(avapritinib)用于胃肠道间质... | 2020-09-29 09:01:24 |
| ·胃肠道间质瘤药瑞普替尼进入乐城先行区 | 2020-07-28 17:38:31 |
| ·美批准Qinlock(ripretinib)用于胃肠道间质瘤 | 2020-05-18 08:41:24 |
| ·基石药业胃肠道间质瘤药Avapritinib申请上市 | 2020-04-23 16:54:27 |
| ·美批准Ayvakit(avapritinib)用于胃肠道间质... | 2020-01-10 10:19:17 |
| ·Ripretinib申请用于胃肠道间质瘤 | 2019-12-18 09:06:11 |
| ·Ripretinib胃肠道间质瘤3期试验获肯定结果 | 2019-08-15 08:58:20 |
| ·Avapritinib申请用于胃肠道间质瘤 | 2019-06-17 10:00:33 |
| ·基石药业Avapritinib获胃肠道间质瘤3期临床批件 | 2019-02-18 14:30:41 |
| ·山西省胃肠道间质瘤流行病学调查 | 2015-03-30 09:29:18 |
| ·亚裔病人更易患胃肠道间质瘤 | 2014-10-13 14:19:45 |
| ·欧洲批准Stivarga(regorafenib)用于胃肠道... | 2014-08-01 14:39:59 |
| ·CHMP支持Stivarga(regorafenib)用于胃... | 2014-07-01 15:06:37 |
| ·Stivarga欧洲申请用于胃肠道间质瘤 | 2013-09-06 14:39:29 |
| ·美批准Stivarga用于胃肠道间质瘤 | 2013-03-28 11:38:46 |
| ·Regorafenib胃肠道间质瘤3期试验公布 | 2012-12-10 11:20:11 |
| ·Stivarga(regorafenib)申请用于胃肠道间质... | 2012-11-01 11:12:18 |
| ·Masitinib申请用于胃肠道间质瘤 | 2012-10-09 10:51:51 |
| ·Regorafenib申请用于胃肠道间质瘤 | 2012-09-03 13:58:02 |
| ·上海市胃肠道间质瘤的临床调查 | 2012-07-20 09:27:48 |
| ·Glivec(伊马替尼)提高胃肠道间质瘤无复发生存期 | 2012-02-29 09:18:09 |
| ·Masitinib胃肠道间质瘤2期试验获肯定结果 | 2012-02-02 14:14:23 |
| ·美批准Gleevec(伊马替尼)用于胃肠道间质瘤术后患者 | 2012-02-01 13:30:38 |
| ·Pazopanib进入软组织肉瘤后期试验 | 2011-06-08 16:16:37 |
| ·Regorafenib胃肠道间质瘤获优先审评 | 2011-05-11 12:11:47 |
| ·Tasigna停止用于胃肠道间质瘤的3期试验 | 2011-04-13 09:28:30 |